Editorial: infliximab or adalimumab as first- or second-line anti-TNF-conflicting evidence-authors' reply.

Visuri, Isabella; Eriksson, Carl; Olén, Ola; Cao, Yang; Mårdberg, Emelie; Grip, Olof; Gustavsson, Anders; Hjortswang, Henrik; Karling, Pontus; Montgomery, Scott; Myrelid, Pär; Ludvigsson, Jonas F; Halfvarson, Jonas

Visuri, Isabella; Eriksson, Carl; Olén, Ola; Cao, Yang; Mårdberg, Emelie; Grip, Olof; Gustavsson, Anders; Hjortswang, Henrik; Karling, Pontus; Montgomery, Scott; Myrelid, Pär; Ludvigsson, Jonas F; Halfvarson, Jonas.

Affiliation

Visuri I; Örebro, Sweden.
Eriksson C; Örebro, Sweden.
Olén O; Stockholm, Sweden.
Cao Y; Stockholm, Sweden.
Mårdberg E; Örebro, Sweden.
Grip O; Örebro, Sweden.
Gustavsson A; Malmö, Sweden.
Hjortswang H; Karlstad, Sweden.
Karling P; Linköping, Sweden.
Montgomery S; Umeå, Sweden.
Myrelid P; Örebro, Sweden.
Ludvigsson JF; Stockholm, Sweden.
Halfvarson J; Linköping, Sweden.

Aliment Pharmacol Ther ; 54(6): 848-849, 2021 09.

Article in En | MEDLINE | ID: mdl-34425010

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Crohn Disease / Tumor Necrosis Factor Inhibitors Limits: Humans Language: En Journal: Aliment Pharmacol Ther Journal subject: FARMACOLOGIA / GASTROENTEROLOGIA / TERAPIA POR MEDICAMENTOS Year: 2021 Document type: Article Affiliation country: Suecia

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google